CCL17 血清水平升高与晚期黑色素瘤患者的生存改善相关。
Increased CCL17 serum levels are associated with improved survival in advanced melanoma.
机构信息
Department of Immunology, University of Tübingen, Tübingen, Germany.
出版信息
Cancer Immunol Immunother. 2015 Sep;64(9):1075-82. doi: 10.1007/s00262-015-1714-4. Epub 2015 May 20.
BACKGROUND
Prognostic factors of melanoma patients with distant metastases remain poorly established. This study aimed to compare the prognostic impact of putative serum biomarkers, namely S100B, YKL-40 or CCL17, in stage IV melanoma patients.
PATIENTS AND METHODS
Serum concentrations were analyzed by ELISA. Disease-specific survival of 80 patients according to S100B, YKL-40 or CCL17 and clinical factors were calculated by univariate Kaplan-Meier survival and multivariate analysis.
RESULTS
Low serum levels of S100B, high concentrations of CCL17 and female gender correlated with improved survival. A trend for favorable prognosis was observed for the M categories M1a/b versus M1c according to the AJCC classification. No correlation with survival was evident for YKL-40 serum levels and age. In multivariate analysis, S100B (HR 2.1; p = 0.005) and CCL17 (HR 1.8; p = 0.029) had independent prognostic impact. Patients with a combination of normal S100B and high CCL17 had a high chance for long-term survival, which was 43 % after 3 years.
CONCLUSION
Serum levels of CCL17 and S100B represent independent prognostic markers for melanoma patients with distant metastases. These biomarkers were more powerful than the M category according to the AJCC classification to indicate overall survival. CCL17 represents a promising biomarker upon immune checkpoint blockade in melanoma.
背景
远处转移的黑色素瘤患者的预后因素仍未得到充分确定。本研究旨在比较潜在的血清生物标志物（即 S100B、YKL-40 或 CCL17）在 IV 期黑色素瘤患者中的预后影响。
患者和方法
通过 ELISA 分析血清浓度。根据 S100B、YKL-40 或 CCL17 和临床因素，通过单变量 Kaplan-Meier 生存和多变量分析计算 80 例患者的疾病特异性生存。
结果
低 S100B 血清水平、高 CCL17 浓度和女性性别与生存改善相关。根据 AJCC 分类，M 类别 M1a/b 与 M1c 相比，预后呈改善趋势。YKL-40 血清水平和年龄与生存无明显相关性。多变量分析显示，S100B（HR 2.1；p = 0.005）和 CCL17（HR 1.8；p = 0.029）具有独立的预后影响。S100B 正常和 CCL17 高的患者有长期生存的高机会，3 年后为 43%。
结论
CCL17 和 S100B 的血清水平是远处转移黑色素瘤患者的独立预后标志物。这些生物标志物比 AJCC 分类中的 M 类别更能指示总生存率。CCL17 是黑色素瘤免疫检查点阻断的有前途的生物标志物。
Zotero 插件